Next Article in Journal
Antioxidative Activity of Soy, Wheat and Pea Protein Isolates Characterized by Multi-Enzyme Hydrolysis
Previous Article in Journal
Nano-Topographical Control of Ti-Nb-Zr Alloy Surfaces for Enhanced Osteoblastic Response
Previous Article in Special Issue
Cytokine-Mediated Inflammation in the Oral Cavity and Its Effect on Lipid Nanocarriers
Review

Use of Protamine in Nanopharmaceuticals—A Review

Department of Pharmaceutical Technology and Biopharmacy, Institute of Pharmaceutical Sciences, Karl-Franzens-University Graz, Universitätsplatz 1, 8010 Graz, Austria
*
Author to whom correspondence should be addressed.
Both authors are contributed equally.
Academic Editors: Ruth Prassl, Angelina Angelova and Horacio Cabral
Nanomaterials 2021, 11(6), 1508; https://doi.org/10.3390/nano11061508
Received: 19 April 2021 / Revised: 27 May 2021 / Accepted: 27 May 2021 / Published: 7 June 2021
(This article belongs to the Special Issue Nanomedicine in Drug Delivery)
Macromolecular biomolecules are currently dethroning classical small molecule therapeutics because of their improved targeting and delivery properties. Protamine-a small polycationic peptide-represents a promising candidate. In nature, it binds and protects DNA against degradation during spermatogenesis due to electrostatic interactions between the negatively charged DNA-phosphate backbone and the positively charged protamine. Researchers are mimicking this technique to develop innovative nanopharmaceutical drug delivery systems, incorporating protamine as a carrier for biologically active components such as DNA or RNA. The first part of this review highlights ongoing investigations in the field of protamine-associated nanotechnology, discussing the self-assembling manufacturing process and nanoparticle engineering. Immune-modulating properties of protamine are those that lead to the second key part, which is protamine in novel vaccine technologies. Protamine-based RNA delivery systems in vaccines (some belong to the new class of mRNA-vaccines) against infectious disease and their use in cancer treatment are reviewed, and we provide an update on the current state of latest developments with protamine as pharmaceutical excipient for vaccines. View Full-Text
Keywords: protamine; proticles; nanoparticles; novel vaccine technologies protamine; proticles; nanoparticles; novel vaccine technologies
Show Figures

Graphical abstract

MDPI and ACS Style

Ruseska, I.; Fresacher, K.; Petschacher, C.; Zimmer, A. Use of Protamine in Nanopharmaceuticals—A Review. Nanomaterials 2021, 11, 1508. https://doi.org/10.3390/nano11061508

AMA Style

Ruseska I, Fresacher K, Petschacher C, Zimmer A. Use of Protamine in Nanopharmaceuticals—A Review. Nanomaterials. 2021; 11(6):1508. https://doi.org/10.3390/nano11061508

Chicago/Turabian Style

Ruseska, Ivana, Katja Fresacher, Christina Petschacher, and Andreas Zimmer. 2021. "Use of Protamine in Nanopharmaceuticals—A Review" Nanomaterials 11, no. 6: 1508. https://doi.org/10.3390/nano11061508

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Back to TopTop